Financial Results : Dallah’s net profit rises 14% in nine-months 2015

Dallah’s net profit rises 14% in nine-months 2015

19/10/2015 Argaam Exclusive

View other reports

 

Dallah Healthcare Holding Co., which operates hospitals and general clinics in Saudi Arabia, reported a net profit of SAR 110.5 million for the first nine months of 2015, marking a 14 percent increase compared to the same period last year on more inpatients and outpatients, and the launch of its North Clinics Building at the beginning of this year



Financials (M)

Item 9m 2014 9m 2015 Change‬
Revenues 619.80 709.55 14.5 %
Gross Income 256.73 290.94 13.3 %
Operating Income 94.85 101.74 7.3 %
Net Income 96.77 110.46 14.2 %
Average Shares 90.00 90.00 -
EPS (Riyals) 1.08 1.23 14.2 %

 

The company reported a net profit of SAR 26.8 million in Q3-2015, a year-on-year growth of 22 percent. When compared to the previous quarter (Q2-2015), the company’s net profit fell 25 percent due to summer vacation, Ramadan, and Eid holidays which usually slow down business.



Current Quarter Comparison (M)

Compared With The
Item Q3 2014 Q3 2015 Change‬
Revenues 192.79 223.93 16.2 %
Gross Income 75.36 87.92 16.7 %
Operating Income 21.67 26.37 21.7 %
Net Income 21.94 26.78 22.1 %
Average Shares 90.00 90.00 -
EPS (Riyals) 0.24 0.30 22.1 %


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2006 - - - - - -
Q2 2006 - - - - - -
Q3 2006 - - - - - -
Q4 2006 - - - - - -
Q1 2007 - - - - - -
Q2 2007 - - - - - -
Q3 2007 - - - - - -
Q4 2007 - - - - - -
Q1 2008 - - - - - -
Q2 2008 - - - - - -
Q3 2008 - - - - - -
Q4 2008 - - - - - -
Q1 2009 - - - - - -
Q2 2009 - - - - - -
Q3 2009 - - - - - -
Q4 2009 - - - - - -
Q1 2010 - - - - - -
Q2 2010 - - - - - -
Q3 2010 104.78 - 36.90 - 18.24 -
Q4 2010 120.09 - 39.97 - 17.35 -
Q1 2011 129.97 - 49.69 - 30.24 -
Q2 2011 139.34 - 50.86 - 26.45 -
Q3 2011 115.44 10.2 % 37.37 1.3 % 16.67 (8.6 %)
Q4 2011 142.59 18.7 % 51.97 30.0 % 27.94 61.0 %
Q1 2012 154.04 18.5 % 72.82 46.5 % 38.00 25.7 %
Q2 2012 161.32 15.8 % 73.73 45.0 % 38.16 44.2 %
Q3 2012 142.26 23.2 % 59.00 57.9 % 22.41 34.4 %
Q4 2012 179.43 25.8 % 81.51 56.9 % 32.18 15.2 %
Q1 2013 183.73 19.3 % 84.40 15.9 % 38.39 1.0 %
Q2 2013 187.79 16.4 % 80.68 9.4 % 30.19 (20.9 %)
Q3 2013 167.08 17.4 % 66.67 13.0 % 21.95 (2.0 %)
Q4 2013 211.05 17.6 % 95.71 17.4 % 48.06 49.3 %
Q1 2014 207.57 13.0 % 87.60 3.8 % 39.73 3.5 %
Q2 2014 219.45 16.9 % 93.78 16.2 % 33.46 10.8 %
Q3 2014 192.79 15.4 % 75.36 13.0 % 21.67 (1.3 %)
Q4 2014 240.08 13.8 % 103.54 8.2 % 50.24 4.5 %
Q1 2015 240.40 15.8 % 102.13 16.6 % 39.67 (0.1 %)
Q2 2015 245.23 11.7 % 100.89 7.6 % 35.71 6.7 %
Q3 2015 223.93 16.2 % 87.92 16.7 % 26.37 21.7 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2006 - - - - - -
Q2 2006 - - - - - -
Q3 2006 - - - - - -
Q4 2006 - - - - - -
Q1 2007 - - - - - -
Q2 2007 - - - - - -
Q3 2007 - - - - - -
Q4 2007 - - - - - -
Q1 2008 - - - - - -
Q2 2008 - - - - - -
Q3 2008 - - - - - -
Q4 2008 - - - - - -
Q1 2009 - - - - - -
Q2 2009 - - - - - -
Q3 2009 - - - - - -
Q4 2009 - - - - - -
Q1 2010 - - - - - -
Q2 2010 - - - - - -
Q3 2010 17.82 - 0.20 - 17.82 0.20
Q4 2010 24.33 - 0.27 - 24.33 0.27
Q1 2011 35.25 - 0.39 - 35.25 0.39
Q2 2011 27.14 - 0.30 - 27.14 0.30
Q3 2011 15.49 (13.1 %) 0.17 - 15.49 0.17
Q4 2011 35.53 46.0 % 0.39 (3.38) 38.91 0.43
Q1 2012 37.96 7.7 % 0.42 - 37.96 0.42
Q2 2012 37.09 36.7 % 0.41 - 37.09 0.41
Q3 2012 23.94 54.5 % 0.27 - 23.94 0.27
Q4 2012 34.37 (3.3 %) 0.38 - 34.37 0.38
Q1 2013 39.04 2.8 % 0.43 - 39.04 0.43
Q2 2013 23.64 (36.3 %) 0.26 - 23.64 0.26
Q3 2013 21.84 (8.7 %) 0.24 - 21.84 0.24
Q4 2013 52.11 51.6 % 0.58 - 52.11 0.58
Q1 2014 40.50 3.7 % 0.45 - 40.50 0.45
Q2 2014 34.33 45.2 % 0.38 - 34.33 0.38
Q3 2014 21.94 0.5 % 0.24 - 21.94 0.24
Q4 2014 50.35 (3.4 %) 0.56 - 50.35 0.56
Q1 2015 47.82 18.1 % 0.53 13.75 34.07 0.38
Q2 2015 35.86 4.4 % 0.40 - 35.86 0.40
Q3 2015 26.78 22.1 % 0.30 - 26.78 0.30

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2006 - - -
Q2 2006 - - -
Q3 2006 - - -
Q4 2006 - - -
Q1 2007 - - -
Q2 2007 - - -
Q3 2007 - - -
Q4 2007 - - -
Q1 2008 - - -
Q2 2008 - - -
Q3 2008 - - -
Q4 2008 - - -
Q1 2009 - - -
Q2 2009 - - -
Q3 2009 - - -
Q4 2009 - - -
Q1 2010 - - -
Q2 2010 - - -
Q3 2010 - - -
Q4 2010 - - -
Q1 2011 - - -
Q2 2011 35.90 % 22.84 % 21.15 %
Q3 2011 35.24 % 22.42 % 20.24 %
Q4 2011 36.01 % 24.05 % 22.15 %
Q1 2012 38.63 % 24.79 % 21.67 %
Q2 2012 41.14 % 25.88 % 22.58 %
Q3 2012 42.90 % 25.84 % 22.97 %
Q4 2012 45.06 % 25.05 % 20.93 %
Q1 2013 44.79 % 24.18 % 20.16 %
Q2 2013 44.08 % 22.36 % 17.45 %
Q3 2013 43.63 % 21.80 % 16.56 %
Q4 2013 43.68 % 23.30 % 18.23 %
Q1 2014 42.75 % 23.14 % 17.85 %
Q2 2014 42.69 % 22.94 % 18.48 %
Q3 2014 42.42 % 22.43 % 17.92 %
Q4 2014 41.90 % 22.11 % 17.11 %
Q1 2015 41.98 % 21.38 % 15.76 %
Q2 2015 41.58 % 21.72 % 15.48 %
Q3 2015 41.54 % 21.77 % 15.49 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2006 - - - -
Q2 2006 - - - -
Q3 2006 - - - -
Q4 2006 - - - -
Q1 2007 - - - -
Q2 2007 - - - -
Q3 2007 - - - -
Q4 2007 - - - -
Q1 2008 - - - -
Q2 2008 - - - -
Q3 2008 - - - -
Q4 2008 - - - -
Q1 2009 - - - -
Q2 2009 - - - -
Q3 2009 - - - -
Q4 2009 - - - -
Q1 2010 - - - -
Q2 2010 - - - -
Q3 2010 90.00 - - 3.67
Q4 2010 90.00 - - 3.94
Q1 2011 90.00 - - 4.29
Q2 2011 90.00 1.16 1.16 4.63
Q3 2011 90.00 1.14 1.14 4.80
Q4 2011 90.00 1.26 1.30 5.21
Q1 2012 90.00 1.29 1.33 5.66
Q2 2012 90.00 1.40 1.44 6.04
Q3 2012 90.00 1.49 1.53 6.31
Q4 2012 90.00 1.48 1.48 12.40
Q1 2013 90.00 1.49 1.49 12.83
Q2 2013 90.00 1.34 1.34 12.37
Q3 2013 90.00 1.32 1.32 12.64
Q4 2013 90.00 1.52 1.52 13.22
Q1 2014 90.00 1.53 1.53 13.75
Q2 2014 90.00 1.65 1.65 13.36
Q3 2014 90.00 1.65 1.65 13.65
Q4 2014 90.00 1.63 1.63 14.15
Q1 2015 90.00 1.72 1.56 14.74
Q2 2015 90.00 1.73 1.58 14.63
Q3 2015 90.00 1.79 1.63 14.86

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2006 - - -
Q2 2006 - - -
Q3 2006 - - -
Q4 2006 - - -
Q1 2007 - - -
Q2 2007 - - -
Q3 2007 - - -
Q4 2007 - - -
Q1 2008 - - -
Q2 2008 - - -
Q3 2008 - - -
Q4 2008 - - -
Q1 2009 - - -
Q2 2009 - - -
Q3 2009 - - -
Q4 2009 - - -
Q1 2010 - - -
Q2 2010 - - -
Q3 2010 - - -
Q4 2010 - - -
Q1 2011 - - -
Q2 2011 - - -
Q3 2011 - - -
Q4 2011 - - -
Q1 2012 - - -
Q2 2012 - - -
Q3 2012 - - -
Q4 2012 25.26 25.26 3.02
Q1 2013 23.15 23.15 2.70
Q2 2013 26.26 26.26 2.85
Q3 2013 26.93 26.93 2.82
Q4 2013 26.15 26.15 3.00
Q1 2014 33.02 33.02 3.69
Q2 2014 33.91 33.91 4.19
Q3 2014 43.67 43.67 5.29
Q4 2014 45.25 45.25 5.23
Q1 2015 40.15 44.08 4.67
Q2 2015 45.84 50.27 5.43
Q3 2015 32.29 35.31 3.88

Business Segments (Million)

Compared With The
Period Medical Services Medicine and Pharmaceutical Products
Q1 2011 118.62 11.35
Q2 2011 132.76 6.58
Q3 2011 110.16 5.99
Q4 2011 134.16 7.73
Q1 2012 141.87 12.17
Q2 2012 148.75 12.57
Q3 2012 133.35 8.91
Q4 2012 163.03 16.20
Q1 2013 169.97 13.76
Q2 2013 168.24 19.56
Q3 2013 158.17 8.92
Q4 2013 192.80 18.25
Q1 2014 195.44 12.12
Q2 2014 201.76 17.69
Q3 2014 177.26 15.52
Q4 2014 223.36 16.72
Q1 2015 224.02 16.38
Q2 2015 228.38 16.85
Q3 2015 215.41 8.52

Analysts Estimates (Million)

Item Q3 2015 (e) Q3 2015 (a) Change‬
Average 32.08 26.78 (16.5 %)

Estimates vs Actual (Million)

Item Q3 2015 (e) Q3 2015 (a) Change
SFC 24.00 26.78 11.6 %
AlJazira Capital 23.90 26.78 12.1 %
OSOOL AND BAKHEET 36.80 26.78 (27.2) %
Value Capital 37.70 26.78 (29.0) %
Albilad Capital 38.00 26.78 (29.5) %

Current
Market Cap (M Riyal) 14,945.04
Enterprise Value (EV) (M) 16,864.64
Shares Outstanding ((M)) 97.68
EPS ( Riyal) (TTM) 4.82
Book Value (BV) ( Riyal) 34.96
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 31.73
P/E (TTM) 31.73
Price/book 4.38
Return on Average Assets (%) (TTM) 7.5
Return on Average Equity (%) (TTM) 14.3

Share Price

153.00
0.00 0.00 %

Dallah Healthcare Co. (DALLAH HEALTH)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.